SCHEDULE: Fresenius Amends Humacyte Stake, Announces Leadership Shifts

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG updated their Schedule 13D filing for Humacyte, Inc., reporting a decreased beneficial ownership percentage due to share dilution and announcing key management changes within Fresenius.

Summary

• Fresenius Medical Care Holdings, Inc. (FMCH) and Fresenius Medical Care AG (FME AG) filed Amendment No. 6 to their Schedule 13D regarding Humacyte, Inc. common stock.
• FMCH beneficially owns 18,312,735 shares of Humacyte Common Stock.
• This ownership represents approximately 9.5% of Humacyte's outstanding voting shares.
• The percentage ownership decreased from 9.9% (as reported in Amendment No. 5) to 9.5% solely due to an increase in Humacyte's total outstanding shares, not from any sale by Fresenius.
• Humacyte had 192,996,511 shares outstanding as of December 15, 2025, including 5,725,190 shares issued on that date.
• Key management changes at FME AG and FMCH were announced, effective January 1, 2026.
• Dr. Charles Hugh-Jones assumed office as a member of the Management Board and Chief Medical Officer of FME AG, and a member of the Board of Directors of FMCH, succeeding Dr. Franklin Maddux.
• Mr. Joseph E. Turk assumed office as a member of the Management Board and Chief Executive Officer of FME AG's global operating segment Care Enablement, succeeding Dr. Katarzyna Mazur-HofsaeSS.

Sentiment

Score: 4

Explanation: The filing primarily reports a decrease in beneficial ownership percentage due to dilution and internal management changes at the reporting entity. While the management changes are neutral, the dilution of the stake is a slight negative for existing shareholders.

Positives

• Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG have not disposed of any shares of Humacyte Common Stock since their initial Schedule 13D filing in September 2021, indicating continued commitment to their investment.

Negatives

• The beneficial ownership percentage of Fresenius in Humacyte decreased from 9.9% to 9.5%, solely due to an increase in Humacyte's total outstanding shares, which represents dilution for existing shareholders.

Risks

• Dilution risk for existing shareholders of Humacyte, Inc. due to the issuance of additional common stock, as evidenced by the increase in outstanding shares from 187,727,321 to 192,996,511.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding Humacyte's business or Fresenius's future investment strategy beyond the current ownership stake.

Industry Context

This filing primarily reflects routine updates to a significant shareholder's stake and internal management changes at the reporting entity (Fresenius Medical Care). It does not provide direct insights into Humacyte's operational performance or broader industry trends, other than the implicit context of Humacyte issuing new shares.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Humacyte, Inc. experienced dilution of their ownership percentage due to the issuance of new shares, which reduced the proportional stake of all existing shareholders.
• Shareholders of Fresenius Medical Care (FME AG and FMCH) saw their indirect ownership percentage in Humacyte decrease, though they did not sell any shares.
• Employees of Fresenius Medical Care are impacted by changes in senior management roles within the company.

Key Dates

Recommendation

The filing indicates a passive dilution of Fresenius's stake in Humacyte, not an active divestment, suggesting Fresenius maintains its investment thesis. The dilution itself is a minor negative for existing shareholders. The management changes are internal to Fresenius and do not directly impact Humacyte's operations or immediate prospects. Therefore, a 'hold' recommendation is appropriate, awaiting further operational or financial updates from Humacyte.

Keywords

Humacyte, Fresenius Medical Care, Schedule 13D, beneficial ownership, share dilution, management changes, corporate governance, common stock, healthcare investment